Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism

Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05114980

Recruitment Status : **RECRUITING NOW**
First Posted : November 10, 2021
Last Update Posted : June 19, 2023

Sponsor:

Information provided by (Responsible Party):
Brenessa Lindeman, University of Alabama at Birmingham

Go to 

Brief Summary:
Options for treatment of severe, refractory hypocalcemia are limited for the thousands of patients in the United States who suffer from hypoparathyroidism. Parathyroid allotransplantation is an emerging treatment that provides hope for these individuals. Currently, this therapy has only been successfully provided by a few centers in the world. In the UAB PATH trial, we propose to become one of the few centers worldwide to successfully achieve parathyroid allotransplantation in transplant-naïve patients.

Hypoparathyroidism
Procedure: Parathyroid Allotransplant
Not Applicable

Show detailed description

Go to 

Layout table for study information

Study Type :
Interventional  (Clinical Trial)

Estimated Enrollment :
5 participants

Allocation:
N/A

Intervention Model:
Single Group Assignment

Masking:
None (Open Label)

Primary Purpose:
Treatment

Official Title:
Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism

Estimated Study Start Date :
July 2024

Estimated Primary Completion Date :
January 2026

Estimated Study Completion Date :
January 2027

Resource links provided by the National Library of Medicine

Go to 

Intervention Details:

Go to 

Primary Outcome Measures :

Parathyroid transplant function [ Time Frame: 8 weeks post-operatively ]
Detectable PTH

Calcium supplementation [ Time Frame: 6 months post-operatively ]
Amount and type of calcium supplements needed post-operatively

Secondary Outcome Measures :

Serum calcium level [ Time Frame: 6 months post-operatively ]
Immunosuppression-related adverse events [ Time Frame: 12 months post-operatively ]
Infections or other adverse events

Go to 

Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:  
18 Years and older   (Adult, Older Adult)

Sexes Eligible for Study:  
All

Accepts Healthy Volunteers:  
No

Inclusion Criteria:

Exclusion Criteria:

Any active malignancy, except non-melanoma skin cancer
Dependence on nursing home or other long-term care provider
History of ischemic cardiomyopathy with ejection fraction <20%, uncontrolled diabetes mellitus (Hgb A1c >10), thrombophilia or other clotting or bleeding disorders, significant heart, liver, kidney or central nervous system disease
History of significant psychiatric illness
Severe osteoporosis
Allergy, hypersensitivity, or intolerance of expected immunosuppressive agents (i.e. Thymoglobulin®, tacrolimus, etc.)
Documented history of gross non-adherence to medical therapies
Significant functional/cognitive impairment without reliable caregiver
Presence of active documented systemic infection or recent systemic infection within the past 3 months
Seropositivity for HIV, HBV core antibody or antigen, HCV, HTLV-1
Current smoker (smoking cessation must have occurred 3 months prior to enrollment)
Chemical and/or alcohol dependency or abuse
Psychosocial problems (including alcoholism, drug abuse, documented behavioral disorders)
Resources deemed inadequate to support necessary post-transplant care

Go to 

Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05114980

Layout table for location information

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35294

Contact: Polina Zmijewski, MD    205-975-5000      

University of Alabama at Birmingham

Layout table for investigator information

Principal Investigator:
Brenessa Lindeman, MD, MEHP
University of Alabama at Birmingham

Go to 

Layout table for additonal information

Responsible Party:
Brenessa Lindeman, Associate Professor of Surgery, University of Alabama at Birmingham

ClinicalTrials.gov Identifier:
NCT05114980    

Other Study ID Numbers:
IRB-3000008285

First Posted:
November 10, 2021    Key Record Dates

Last Update Posted:
June 19, 2023

Last Verified:
June 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:
No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:
No

Studies a U.S. FDA-regulated Device Product:
No

Additional relevant MeSH terms:

Layout table for MeSH terms

HypoparathyroidismParathyroid DiseasesEndocrine System Diseases
Parathyroid HormoneCalcium-Regulating Hormones and AgentsPhysiological Effects of Drugs

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 19, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments